Medical/Pharmaceuticals
Operating Income of Yiling Pharmaceutical in First 3 Quarters Reaches CNY 8.112 Billion, Up 25.81%
SHIJIAZHUANG, China, Oct. 29, 2021 /PRNewswire/ -- Yiling Pharmaceutical released the three-quarter report on the evening ofOctober 28. In the first three quarters, the operating income of the company reachedCNY 8.112 billion, up 25.81% year on year; the net profit attributable to shareholders of...
2021-10-29 17:17
2052
3M Health Care and Thermo Fisher Scientific Collaborate to Increase Process Efficiency and Scalability in Commercial Therapeutic Manufacturing
- Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers - Solution enables manufacturers to optimize manufacturing capacity, quality, efficiency and scalability ST. PAUL, Minn., Oct. 29, 2021 /PRNewswire/ -- 3M Separation and Purification ...
2021-10-29 15:45
2367
Elekta establishes a framework for sustainability-linked bonds
STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that it has established a Sustainability-Linked Bond Framework (SLB Framework) for issues of sustainability-linked bonds under itsMedium Term Note Program (MTN-Program). Elekta is among the first companies inSweden to est...
2021-10-29 15:29
3392
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA
SHANGHAI, Oct. 29, 2021 /PRNewswire/ -- IMPACT Therapeutics announced that its ATR inhibitor IMP9064 has received the IND clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, which will begin soon in the U.S. This will be the first in human study for the A...
2021-10-29 14:12
2478
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 inChina (ENREACH-LUNG-02) recently completed the first drug administration. ENREACH-LUNG-02 is a multi-center, open-label, randomized...
2021-10-29 09:36
3161
Hanmi Science Consortium Drives Ambitious Project for Worldwide Vaccine Equity
SEOUL, South Korea, Oct. 29, 2021 /PRNewswire/ -- Hanmi Science doesn't just want the world to know they are committed to vaccine equity, they want to prove it. Mr. Lim, CEO of Hanmi Science, echoes the concerns of Mr.Bill Gates, co-founder of the Bill & Melinda Gates Foundation. As Mr. Gates sta...
2021-10-29 09:27
3295
Exosystems Raises $3.9M Series A Funding, on Mission to Provide AI-based Digital Care for Musculoskeletal System
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Exosystems, an artificial intelligence (AI)-based digital healthcare company and a member ofBorn2Global Centre, has succeeded in attracting Series A funding worth USD 3.9 million from SBI Investment, Laguna Investment, and Korea Technology Finance...
2021-10-29 07:47
2252
World Stroke Day: Global survey reveals only 35% hospitals worldwide provide essential stroke treatment
GENEVA, Oct. 29, 2021 /PRNewswire/ -- On World Stroke Day, 29 October, the World Stroke Organization (WSO) is calling for urgent action after a survey by the WSO and the World Health Organization (WHO) found that only 35% of hospitals worldwide provide essential clot-busting medicine tissue plasm...
2021-10-29 06:01
2060
ImmunoForge Inc. receives U.S. FDA ODD for PF1801
SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...
2021-10-29 05:50
4404
EZZ Marks Transition to Genomic Health Following Exceptional FY21 Performance
About EZZ Life Science Holdings EZZ Life Science Holding Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papi...
2021-10-29 04:05
4596
FII Institute Announces Investment in AZmed, Helping to Address Global Shortage in Radiologists
RIYADH, Saudi Arabia, Oct. 28, 2021 /PRNewswire/ -- The Future Investment
Initiative (FII) Institute has announced a1 million EUR investment in AZmed,
developers of Artificial Intelligence-enabled diagnostic applications which can
help address the shortage of radiologists around the world.
2021-10-28 23:15
4349
Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...
2021-10-28 21:00
1859
Osfirm to Launch Novel Implantable Biomaterial Whitlockite with Excellent Biodegradability and Bone Regenerative and Reconstructive Properties into Global Market by the Year 2023
SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In 1941, "whitlockite," the second most abundant inorganic mineral of the bone was named in honor of Herbert Whitlockite, Curator of Minerals and Gems in the American Museum of Natural History inNew York. Whitlockite is a unique form of magnesium ...
2021-10-28 21:00
1859
Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies
- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract...
2021-10-28 21:00
4282
HanAll Biopharma Reports Third Quarter 2021 Results
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...
2021-10-28 21:00
2715
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...
2021-10-28 20:00
3982
Interim report for Q3 2021 : Bactiguard Holding AB (publ)
STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...
2021-10-28 15:23
2368
Mentice publishes the company's interim report for the period January-September 2021
STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Third quarter (July–September 2021) and the first nine months of the year (January-September 2021) * Order intake amounted to 51.8 (34.6) MSEK for the third quarter and 131.9 (95.5) MSEK for the first nine months of the year. * Order book by the end ...
2021-10-28 15:07
2006
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...
2021-10-28 08:30
2607
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China
SAN FRANCISCO and SUZHOU, China, Oct. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-10-28 08:00
4063
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
Nuix Recognised as a RiskTech100® 2027 Disruptor by Chartis Research
[Picked up by 274 media titles]
2026-09-25 08:30Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13806
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12522
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11554
